Live
- Air India Express row: 'Company leadership available for discussions', CEO says in letter to employees
- 'When will Shiv Sena-UBT merge with Congress', asks BJP & Shinde camp
- RBI lifts ban on Bank of Baroda's BoB World
- Youth should come forward for blood donation: District Medical Officer Dr. Sudhakar Lal
- Grand Farewell Day Celebrations in Government Degree College
- PM Modi holds roadshow in Vijayawada with Chandrababu Naidu, Pawan Kalyan
- Farmers should be alerted: District Collector Uday Kumar
- 95 more Myanmar refugees enter Mizoram to avoid 'forceful' induction in militant outfit
- Punish Congress for Pitroda's 'racial' comments: PM Modi
- RML Hospital bribery case: CBI books over 15 including 2 doctors
Hyderabad: Balaxi Pharma posts Rs 10 crore net in Q2
Balaxi Pharma posts Rs 10 crore net in Q2
City-based Balaxi Pharmaceuticals Limited (BPL) reported Rs 60.3 crore revenue for the second quarter ended September 2020
Hyderabad: City-based Balaxi Pharmaceuticals Limited (BPL) reported Rs 60.3 crore revenue for the second quarter ended September 2020. It reported an EBITDA of Rs 10.3 crore and a net profit of Rs 10.1 crore during the period.
During the first half of current fiscal, it posted a total revenue of Rs 112.4 crore. The EBITDA stood Rs 19.3 crore while net profit came at Rs 18.8 crore. Ashish Maheshwari, company's Chairman and Managing Director, said: "We are delighted to report a decent growth in our business amidst Covid-19 pandemic.
The company has 548 pharmaceutical product registrations spanning across five countries and 582 product registrations in pipeline.
We also have a well-established expert regulatory team, which carefully monitors the registration process at every stage. We aim to double our pharmaceutical product registrations over next 2 years."
